biostudies-literatureBinks MJNational Health and Medical Research Council13https://www.ebi.ac.uk/biostudies/studies/S-EPMC6305569biostudies-literatureUnknown10<h4>Background</h4>Indigenous children in Australia's Northern Territory are densely colonised with the pneumococcus within weeks of birth antecedent to a high prevalence of acute lower respiratory infection (ALRI). We assessed the impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in pregnancy against infant ALRI in this setting.<h4>Methods</h4>In an open label, allocation concealed, outcome-assessor blinded, randomised controlled trial conducted in the Northern Territory of Australia, healthy Indigenous women aged 17-39 years were randomised to receive the 23vPPV during pregnancy (<i>n</i> = 75; 30-36 weeks gestation), at birth (<i>n</i> = 75), or at 7 months post-partum (<i>n</i> = 77). Randomisation was stratified by community of residence. In a secondary analysis, wePneumonia (Nathan Qld.)Impact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia.PMC63055691017225350499 &amp; 490320Mulholland KNelson JBinks MJLeach AJHare KMAndrews RMWilson CMorris PSNelson SMoberley SABalloch ATorzillo PJCarapetis JRWare RSTang MLKfalseImpact of the 23-valent pneumococcal polysaccharide vaccination in pregnancy against infant acute lower respiratory infections in the Northern Territory of Australia.<h4>Background</h4>Indigenous children in Australia's Northern Territory are densely colonised with the pneumococcus within weeks of birth antecedent to a high prevalence of acute lower respiratory infection (ALRI). We assessed the impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in pregnancy against infant ALRI in this setting.<h4>Methods</h4>In an open label, allocation concealed, outcome-assessor blinded, randomised controlled trial conducted in the Northern Territory of Australia, healthy Indigenous women aged 17-39 years were randomised to receive the 23vPPV during pregnancy (<i>n</i> = 75; 30-36 weeks gestation), at birth (<i>n</i> = 75), or at 7 months post-partum (<i>n</i> = 77). Randomisation was stratified by community of residence. In a secondary analysis, we2018-01-01T00:00:00Z20182026-05-06T01:02:56.284Z2019-03-26T22:33:43ZS-EPMC63055693060337610.1186/s41479-018-0057-2